Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLDR with Chemotherapy for NSCLC and Esophageal Cancer
NCT03094884Phase 1Unknown
- Sponsor
- Fox Chase Cancer Center
- Start
- Feb 2017
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in non-small cell lung cancer (NSCLC) and esophageal cancer, sponsored by Fox Chase Cancer Center. Primary endpoint: Rate of severe acute esophagitis at 2 years. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)esophageal cancer
Beyond the preview
Go deeper on NCT03094884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03094884.